Long-term follow-up of percutaneous secundum-type atrial septal defect closure using Amplatzer Septal Occluder since 1995: a single-centre study.

Introduction: The goal of this single-centre study was to evaluate long-term results of percutaneous closure of secundum-type atrial septal defect using Amplatzer Septal Occluder with the follow-up to 25 years.

Methods: A retrospective analysis of patients who underwent percutaneous closure of secundum-type atrial septal defect between September 1995 and October 2012 in our institution was performed. All procedures were performed after fulfilling strict indication criteria.

First experience with AndraStent XL implantation in children and adolescents with congenital heart diseases.

Objectives: To present our experience with a new type of extra-large (dilatable up to 25 mm), balloon-expandable, nonpremounted, cobalt-chromium peripheral stent with semiopen designed cells: AndraStent.

Methods: Between December 2008 and August 2011, 21 AndraStents in 21 patients were implanted into vessel stenoses of varied localizations. AndraStents XL of 21, 30, and 39 mm in length were used.

The new Amplatzer duct occluder II: when is its use advantageous?

Objectives: To determine the safety and efficacy of the Amplatzer duct occluder and the Amplatzer duct occluder II in different types of arterial ducts, and to determine in which types of ducts the use of this new device can be advantageous.

Methods: All children with a device-based ductal closure between September, 2005 and February, 2010 were included. We retrospectively analysed the catheterisation and follow-up data.

Percutaneous management of cyanosis in Fontan patients using Amplatzer occluders.

Objectives: To determine causes of cyanosis and to evaluate percutaneous management of cyanosis in a group of consecutive Fontan patients.

Background: A variety of communications allow a right-to-left shunt in Fontan circulation causing cyanosis and these communications are amenable to percutaneous closure.

Methods: Between November 1997 and November 2007, 45 consecutive patients ranging in age from 2.

Long-term outcome of transcatheter patent ductus arteriosus closure using Amplatzer duct occluders.

Background: Immediate-, short-, and intermediate-term results of percutaneous patent ductus arteriosus (PDA) closure using Amplatzer duct occluders are excellent. However, long-term results have not yet been reported to date.

Methods: Between September 1996 and April 2002, 64 consecutive patients having isolated PDA with minimal diameter of > or =2 mm underwent percutaneous closure using Amplatzer duct occluders.